Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM - PACE-CME

Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Myosin inhibitors: recent clinical data and applications in HCM and HF
Myosin inhibitors: recent clinical data and applications in HCM and HF
MinuteCE®
Myosin inhibitors: recent clinical data and applications in HCM and HF
0.75 program credits
- Caroline Coats, MD
0.75 program credits
Epidemiology and clinical features of HCM
Epidemiology and clinical features of HCM
MinuteCE®
Epidemiology and clinical features of HCM
0.75 program credits
- Perry Elliott, MD
0.75 program credits
Aficamten improves peak oxygen uptake in obstructive HCM
Aficamten improves peak oxygen uptake in obstructive HCM
Hypertrophic Cardiomyopathy
Aficamten improves peak oxygen uptake in obstructive HCM
- Caroline Coats, MD
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
ACC.24
Targeting cardiac energetics with cardiac mitotrope in nonobstructive HCM
- Martin Maron, MD